Manufacturer of Controlled Substances; Notice of Registration; Cody Laboratories, Inc., 12103-12104 [2013-03881]
Download as PDF
<![CDATA[
12103
Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices
Drug
Schedule
erowe on DSK2VPTVN1PROD with NOTICES
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Remifentanil (9739) ......................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
I
I
I
I
I
14:47 Feb 20, 2013
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Application; GE
Healthcare
I
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 31, 2012,
GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease; and to manufacture
a bulk investigational new drug (IND)
for clinical trials.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 229001
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
[FR Doc. 2013–03893 Filed 2–20–13; 8:45 am]
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
VerDate Mar<15>2010
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03895 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application;
Alltech Associates, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 19,
2012, Alltech Associates Inc., 2051
Waukegan Road, Deerfield, Illinois
60015, made application to the Drug
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
5-Methoxy-N–Ndimethyltryptamine (7431).
2C–E
(2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509).
2C–H
(2-(2,5Dimethoxyphenyl)ethanamine)
(7517).
2C–T–4 (2-(4-isopropylthio)-2,5dimethoxyphenyl) ethanamine)
(7532).
Schedule
I
I
I
I
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03919 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cody Laboratories, Inc.
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67398,
Cody Laboratories, Inc., ATTN: Richard
Asherman, 601 Yellowstone Avenue,
Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Dihydromorphine (9145) ................
Amphetamine (1100) ......................
Methamphetamine (1105) ..............
E:\FR\FM\21FEN1.SGM
21FEN1
Schedule
I
II
II
12104
Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices
Schedule
Drug
Amobarbital (2125) .........................
Pentobarbital (2270) .......................
Secobarbital (2315) ........................
4-Anilino-N-phenethyl-4-piperidine
(ANPP) (8333).
Phenylacetone (8501) ....................
Cocaine (9041) ...............................
Codeine (9050) ..............................
Dihydrocodeine (9120) ...................
Oxycodone (9143) ..........................
Hydromorphone (9150) ..................
Diphenoxylate (9170) .....................
Ecgonine (9180) .............................
Hydrocodone (9193) ......................
Meperidine (9230) ..........................
Methadone (9250) ..........................
Morphine (9300) .............................
Thebaine (9333) .............................
Oxymorphone (9652) .....................
Alfentanil (9737) .............................
Remifentanil (9739) ........................
Sufentanil (9740) ............................
Fentanyl (9801) ..............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
[FR Doc. 2013–03881 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
erowe on DSK2VPTVN1PROD with NOTICES
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
By Notice dated November 5, 2012,
and published in the Federal Register
14:47 Feb 20, 2013
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Regarding the drug code (8333), the
company plans to use this controlled
substance to manufacture another
controlled substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cedarburg Pharmaceuticals, Inc., to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03885 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Jkt 229001
Drug Enforcement Administration
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67398, InB
Hauser Pharmaceutical Services, Inc.,
6880 N. Broadway, Suite H, Denver,
Colorado 80221, made application by
letter to the Drug Enforcement
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
Administration (DEA) to be registered as
a bulk manufacturer of 4-Anilino-Nphenethyl-4-piperidine (8333), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution and sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of InB
Hauser Pharmaceutical Services, Inc., to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated InB Hauser Pharmaceutical
Services, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03886 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
Proposed Collection of Information;
Comment Request
National Endowment for the
Arts, National Foundation on the Arts
and the Humanities.
ACTION: Notice. Proposed collection;
comment request.
AGENCY:
The National Endowment for
the Arts (NEA), as part of its continuing
effort to reduce paperwork and
respondent burden, conducts a
preclearance consultation program to
provide the general public and federal
agencies with an opportunity to
comment on proposed and/or
continuing collections of information in
accordance with the Paperwork
Reduction Act of 1995 (PRA95) [44
U.S.C. 3506(c)(A)]. This program helps
to ensure that requested data can be
provided in the desired format,
reporting burden (time and financial
SUMMARY:
Manufacturer of Controlled
Substances; Notice of Registration;
INB Hauser Pharmaceutical Services,
Inc.
DEPARTMENT OF JUSTICE
VerDate Mar<15>2010
Schedule
4-Anilino-N-phenethyl-4-piperidine
ANPP) (8333).
Fentanyl (9801) ............................
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of Cody
Laboratories, Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Cody Laboratories, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
on November 13, 2012, 77 FR 67676,
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
E:\FR\FM\21FEN1.SGM
21FEN1
]]>Agencies
[Federal Register Volume 78, Number 35 (Thursday, February 21, 2013)]
[Notices]
[Pages 12103-12104]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03881]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Cody Laboratories, Inc.
By Notice dated November 1, 2012, and published in the Federal
Register on November 9, 2012, 77 FR 67398, Cody Laboratories, Inc.,
ATTN: Richard Asherman, 601 Yellowstone Avenue, Cody, Wyoming 82414,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the following basic
classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)...................... I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
[[Page 12104]]
Amobarbital (2125).......................... II
Pentobarbital (2270)........................ II
Secobarbital (2315)......................... II
4-Anilino-N-phenethyl-4-piperidine (ANPP) II
(8333).
Phenylacetone (8501)........................ II
Cocaine (9041).............................. II
Codeine (9050).............................. II
Dihydrocodeine (9120)....................... II
Oxycodone (9143)............................ II
Hydromorphone (9150)........................ II
Diphenoxylate (9170)........................ II
Ecgonine (9180)............................. II
Hydrocodone (9193).......................... II
Meperidine (9230)........................... II
Methadone (9250)............................ II
Morphine (9300)............................. II
Thebaine (9333)............................. II
Oxymorphone (9652).......................... II
Alfentanil (9737)........................... II
Remifentanil (9739)......................... II
Sufentanil (9740)........................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans on manufacturing the listed controlled substances
in bulk for sale to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Cody Laboratories, Inc., to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Cody Laboratories, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-03881 Filed 2-20-13; 8:45 am]
BILLING CODE 4410-09-P
